Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Meeting Abstracts

Focusing the immune response on protective epitopes: A new approach to vaccine design using classical immunologic principles

Susan Zolla-Pazner
Susan Zolla-Pazner
New York University School of Medicine, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2008
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Protective antibodies (Abs) are needed to reduce the size of a virus inoculum and block infection of target cells. Since sera from some HIV-infected individuals have broad neutralizing activity and several human monoclonal Abs neutralize a broad spectrum of primary isolates, it is clear that the human B-cell repertoire includes genes capable of coding for broadly protective Abs. The epitopes that are known to induce broadly neutralizing Abs include the membrane proximal external region of gp41, the CD4 binding site on gp120, complex glycans on gp120, the CD4-induced epitope in and around the gp120 bridging sheet, and the V3 loop of gp120.

Despite the extensive information on HIV neutralizing Abs, it has proven difficult to induce broadly neutralizing Ab responses against HIV by immunization. This is due to several factors including the predominant induction of non-neutralizing rather than neutralizing Abs, the masking of neutralization-sensitive epitopes, the high mutation rate of HIV leading to antigenic variability, the physicochemical characteristics of the virus membrane, and the variable affinities of the different gp120 proteins for the virus receptors.

While various forms of the HIV envelope proteins have been used as immunogens, the best, albeit modest, results in terms of generating broadly neutralizing Abs have been achieved with strategies utilizing a DNA prime and either a recombinant adenovirus or protein boost. An alternative immunization approach is the construction and use of an immunogen that will focus the immune response on one or a few epitopes that are known to induce neutralizing Abs. An advantage of this approach is the potential to induce an immune response with a larger proportion of neutralizing Abs. To test the concept of "immunofocusing vaccines," we developed an immunization regimen designed to focus the immune response on the V3 loop of the HIV envelope. For this, we used both classical immunologic approaches and more recent data that stress the importance of the conformation of B cell epitopes to prime and selectively stimulate memory B cells.

Here, we report the results of experiments in rabbits in which animals were primed with gp120 DNA and boosted with a V3-fusion protein in order to preferentially induce anti-V3 Abs. The results provide a proof-of-principle that it is possible to focus the immune response on a neutralizing epitope and induce a vigorous neutralizing anti-HIV Ab response. The results suggest that immunofocusing vaccine regimens do indeed, target Abs to particular epitopes. This approach can now be employed to provide a platform for inducing Abs of greater potency and breadth by defining the best combinations of strains from which to build the priming and boosting immunogens and by designing immunogens that will optimally present several neutralizing epitopes.

This abstract was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research.

  • Copyright © 2008 by Susan Zolla-Pazner
PreviousNext
Back to top
Cancer Immunity Archive: 8 (Suppl 1)
January 2008
Volume 8, Issue Suppl 1
  • Table of Contents

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Focusing the immune response on protective epitopes: A new approach to vaccine design using classical immunologic principles
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Focusing the immune response on protective epitopes: A new approach to vaccine design using classical immunologic principles
Susan Zolla-Pazner
Cancer Immun January 1 2008 (8) (Suppl 1) 4;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Focusing the immune response on protective epitopes: A new approach to vaccine design using classical immunologic principles
Susan Zolla-Pazner
Cancer Immun January 1 2008 (8) (Suppl 1) 4;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • The collaboration for AIDS vaccine discovery: A model for accelerating research
  • Robust T-cell responses and clinical responses following long peptide vaccination against high risk HPV-16
  • Human monoclonal antibodies and analytic vaccinology
Show more Meeting Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement